Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10553639 | 0.81 | LMNA (0.48) | LMNAMMP1MMP2MMP3MMP9 | |
| SCHEMBL7078022 | 0.81 | — | — | |
| SCHEMBL21448749 | 0.81 | MMP1 (0.34) | LMNAMMP1MMP2MMP3MMP9 | |
| SCHEMBL8982550 | 0.79 | SLC7A5 (0.41) | LMNAMMP1MMP2MMP3MMP9 | |
| SCHEMBL14753124 | 0.79 | ALDH1A1 (0.50) | LMNAPRKCATSHRMAPTMAPK1 | |
| SCHEMBL6892355 | 0.79 | ALDH1A1 (0.50) | LMNAPRKCATSHRMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL593628 | 0.79 | LMNA (0.52) | LMNACYP1A2GABRR1TSHRMAPT | |
| SCHEMBL28875655 | 0.77 | TSHR (0.59) | LMNATSHRMAPTKDM4E | |
| SCHEMBL6899594 | 0.76 | MMP1 (0.59) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL6895534 | 0.76 | MMP1 (0.59) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | REN, ACE, AGT | LMNA 348/4885MMP1 165/4885MMP2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.